Cargando…

Chronic Recurrent Multifocal Osteomyelitis in Pediatric Crohn Disease, A Paradoxical Effect to Antitumor Necrosis Factor Alpha

Tumor necrosis factor-α (TNF-α) inhibitors have resulted in significant progress in the treatment of chronic inflammatory diseases. However, these therapies can lead to paradoxical immune-mediated inflammatory diseases with unknown physiopathology. For the first time, we report 3 cases of paradoxica...

Descripción completa

Detalles Bibliográficos
Autores principales: Cordesse, Anne, Ecochard-Dugelay, Emmanuelle, Melki, Isabelle, Caseris, Marion, Belarbi, Nadia, Hugot, Jean-Pierre, Viala, Jerome, Martinez-Vinson, Christine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10191537/
https://www.ncbi.nlm.nih.gov/pubmed/37206602
http://dx.doi.org/10.1097/PG9.0000000000000007
_version_ 1785043482764640256
author Cordesse, Anne
Ecochard-Dugelay, Emmanuelle
Melki, Isabelle
Caseris, Marion
Belarbi, Nadia
Hugot, Jean-Pierre
Viala, Jerome
Martinez-Vinson, Christine
author_facet Cordesse, Anne
Ecochard-Dugelay, Emmanuelle
Melki, Isabelle
Caseris, Marion
Belarbi, Nadia
Hugot, Jean-Pierre
Viala, Jerome
Martinez-Vinson, Christine
author_sort Cordesse, Anne
collection PubMed
description Tumor necrosis factor-α (TNF-α) inhibitors have resulted in significant progress in the treatment of chronic inflammatory diseases. However, these therapies can lead to paradoxical immune-mediated inflammatory diseases with unknown physiopathology. For the first time, we report 3 cases of paradoxical chronic recurrent multifocal osteomyelitis after infliximab or adalimumab therapy during the course of Crohn disease. The patients complained of bone pain without joint involvement. At the time of diagnosis of paradoxical reaction, all patients were in remission due to anti-TNFα efficiency. Trough levels of anti-TNFα were in the expected range, and there were no anti–anti-TNFα antibodies. The duration of treatment was between 2 and 26 months. Other causes of CRMO were excluded. All patients recovered after discontinuation of infliximab (n = 2) or adalimumab (n = 1). The increasing use of these therapies leads to new descriptions of paradoxical effects, which clinicians should be aware of.
format Online
Article
Text
id pubmed-10191537
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-101915372023-05-18 Chronic Recurrent Multifocal Osteomyelitis in Pediatric Crohn Disease, A Paradoxical Effect to Antitumor Necrosis Factor Alpha Cordesse, Anne Ecochard-Dugelay, Emmanuelle Melki, Isabelle Caseris, Marion Belarbi, Nadia Hugot, Jean-Pierre Viala, Jerome Martinez-Vinson, Christine JPGN Rep Case Report Tumor necrosis factor-α (TNF-α) inhibitors have resulted in significant progress in the treatment of chronic inflammatory diseases. However, these therapies can lead to paradoxical immune-mediated inflammatory diseases with unknown physiopathology. For the first time, we report 3 cases of paradoxical chronic recurrent multifocal osteomyelitis after infliximab or adalimumab therapy during the course of Crohn disease. The patients complained of bone pain without joint involvement. At the time of diagnosis of paradoxical reaction, all patients were in remission due to anti-TNFα efficiency. Trough levels of anti-TNFα were in the expected range, and there were no anti–anti-TNFα antibodies. The duration of treatment was between 2 and 26 months. Other causes of CRMO were excluded. All patients recovered after discontinuation of infliximab (n = 2) or adalimumab (n = 1). The increasing use of these therapies leads to new descriptions of paradoxical effects, which clinicians should be aware of. Lippincott Williams & Wilkins 2020-08-20 /pmc/articles/PMC10191537/ /pubmed/37206602 http://dx.doi.org/10.1097/PG9.0000000000000007 Text en Copyright © 2020 The Author(s). Published by Wolters Kluwer on behalf of European Society for Pediatric Gastroenterology, Hepatology, and Nutrition and North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY) (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Cordesse, Anne
Ecochard-Dugelay, Emmanuelle
Melki, Isabelle
Caseris, Marion
Belarbi, Nadia
Hugot, Jean-Pierre
Viala, Jerome
Martinez-Vinson, Christine
Chronic Recurrent Multifocal Osteomyelitis in Pediatric Crohn Disease, A Paradoxical Effect to Antitumor Necrosis Factor Alpha
title Chronic Recurrent Multifocal Osteomyelitis in Pediatric Crohn Disease, A Paradoxical Effect to Antitumor Necrosis Factor Alpha
title_full Chronic Recurrent Multifocal Osteomyelitis in Pediatric Crohn Disease, A Paradoxical Effect to Antitumor Necrosis Factor Alpha
title_fullStr Chronic Recurrent Multifocal Osteomyelitis in Pediatric Crohn Disease, A Paradoxical Effect to Antitumor Necrosis Factor Alpha
title_full_unstemmed Chronic Recurrent Multifocal Osteomyelitis in Pediatric Crohn Disease, A Paradoxical Effect to Antitumor Necrosis Factor Alpha
title_short Chronic Recurrent Multifocal Osteomyelitis in Pediatric Crohn Disease, A Paradoxical Effect to Antitumor Necrosis Factor Alpha
title_sort chronic recurrent multifocal osteomyelitis in pediatric crohn disease, a paradoxical effect to antitumor necrosis factor alpha
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10191537/
https://www.ncbi.nlm.nih.gov/pubmed/37206602
http://dx.doi.org/10.1097/PG9.0000000000000007
work_keys_str_mv AT cordesseanne chronicrecurrentmultifocalosteomyelitisinpediatriccrohndiseaseaparadoxicaleffecttoantitumornecrosisfactoralpha
AT ecocharddugelayemmanuelle chronicrecurrentmultifocalosteomyelitisinpediatriccrohndiseaseaparadoxicaleffecttoantitumornecrosisfactoralpha
AT melkiisabelle chronicrecurrentmultifocalosteomyelitisinpediatriccrohndiseaseaparadoxicaleffecttoantitumornecrosisfactoralpha
AT caserismarion chronicrecurrentmultifocalosteomyelitisinpediatriccrohndiseaseaparadoxicaleffecttoantitumornecrosisfactoralpha
AT belarbinadia chronicrecurrentmultifocalosteomyelitisinpediatriccrohndiseaseaparadoxicaleffecttoantitumornecrosisfactoralpha
AT hugotjeanpierre chronicrecurrentmultifocalosteomyelitisinpediatriccrohndiseaseaparadoxicaleffecttoantitumornecrosisfactoralpha
AT vialajerome chronicrecurrentmultifocalosteomyelitisinpediatriccrohndiseaseaparadoxicaleffecttoantitumornecrosisfactoralpha
AT martinezvinsonchristine chronicrecurrentmultifocalosteomyelitisinpediatriccrohndiseaseaparadoxicaleffecttoantitumornecrosisfactoralpha